Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.
IMMU-132
sacituzumab govitecan
trop-2
uterine carcinosarcoma
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
04 Feb 2020
04 Feb 2020
Historique:
received:
19
07
2019
accepted:
26
10
2019
entrez:
22
2
2020
pubmed:
23
2
2020
medline:
23
2
2020
Statut:
epublish
Résumé
Uterine and ovarian carcinosarcomas (CS) are rare cancers with poor prognosis. Sacituzumab-govitecan (SG) is a new class of antibody-drug-conjugate (ADC) targeting the human-trophoblast-cell-surface marker (Trop-2) conjugated with the active metabolite of irinotecan (SN-38). We evaluated the efficacy of SG against biologically aggressive CS. Trop-2 expression was evaluated in 10 formalin-fixed-paraffined-embedded (FFPE) CS by immunohistochemistry and 9 primary CS cell-lines by flow-cytometry. One Trop-2 low/negative (SARARK14) and two Trop-2 positive (SARARK4, SARARK9) cell-lines were tested in cell-viability assays . The Strong/diffuse staining was seen in 30% (3/10) of FFPE tumors and 33% (3/9) of primary CS cell lines. Trop-2 positive cell-lines (SARARK4, SARARK9) showed higher sensitivity to SG SG may represent a novel class of active drugs for carcinosarcomas patients overexpressing Trop-2.
Sections du résumé
BACKGROUND
BACKGROUND
Uterine and ovarian carcinosarcomas (CS) are rare cancers with poor prognosis. Sacituzumab-govitecan (SG) is a new class of antibody-drug-conjugate (ADC) targeting the human-trophoblast-cell-surface marker (Trop-2) conjugated with the active metabolite of irinotecan (SN-38). We evaluated the efficacy of SG against biologically aggressive CS.
METHODS
METHODS
Trop-2 expression was evaluated in 10 formalin-fixed-paraffined-embedded (FFPE) CS by immunohistochemistry and 9 primary CS cell-lines by flow-cytometry. One Trop-2 low/negative (SARARK14) and two Trop-2 positive (SARARK4, SARARK9) cell-lines were tested in cell-viability assays . The
RESULTS
RESULTS
Strong/diffuse staining was seen in 30% (3/10) of FFPE tumors and 33% (3/9) of primary CS cell lines. Trop-2 positive cell-lines (SARARK4, SARARK9) showed higher sensitivity to SG
CONCLUSION
CONCLUSIONS
SG may represent a novel class of active drugs for carcinosarcomas patients overexpressing Trop-2.
Identifiants
pubmed: 32082489
doi: 10.18632/oncotarget.27342
pii: 27342
pmc: PMC7007291
doi:
Types de publication
Journal Article
Langues
eng
Pagination
560-570Subventions
Organisme : NCI NIH HHS
ID : P30 CA016359
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA176067
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright: © 2019 Lopez et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors also declare no conflicts of interest
Références
Clin Cancer Res. 2014 Sep 1;20(17):4436-41
pubmed: 24879797
Cancer Cell. 2017 Mar 13;31(3):411-423
pubmed: 28292439
Clin Cancer Res. 2015 Sep 1;21(17):3870-8
pubmed: 25944802
Nat Commun. 2014 Sep 19;5:5006
pubmed: 25233892
J Clin Pathol. 2009 Feb;62(2):152-8
pubmed: 18930986
Mod Pathol. 2008 Feb;21(2):186-91
pubmed: 18084248
J Clin Oncol. 2018 Jul 10;36(20):2044-2051
pubmed: 29584549
Cancer Lett. 2009 Feb 8;274(1):47-53
pubmed: 18929442
J Clin Oncol. 2002 Feb 1;20(3):719-26
pubmed: 11821453
Anticancer Res. 2013 Dec;33(12):5461-9
pubmed: 24324082
Bioconjug Chem. 2015 May 20;26(5):919-31
pubmed: 25915780
Br J Cancer. 2010 Jan 5;102(1):134-43
pubmed: 19920829
Int J Colorectal Dis. 2009 Aug;24(8):875-84
pubmed: 19421758
Clin Genitourin Cancer. 2016 Feb;14(1):e75-9
pubmed: 26541586
Proc Natl Acad Sci U S A. 1981 Aug;78(8):5147-50
pubmed: 7029529
Discov Med. 2018 Jun;25(140):309-319
pubmed: 30021104
J Clin Oncol. 2017 Aug 20;35(24):2790-2797
pubmed: 28548889
Oncotarget. 2018 Jun 22;9(48):28989-29006
pubmed: 29989029
Int J Gynecol Cancer. 2011 Dec;21(9):1613-21
pubmed: 21892093
Clin Cancer Res. 2017 Oct 1;23(19):5711-5719
pubmed: 28679770
Clin Cancer Res. 2011 May 15;17(10):3157-69
pubmed: 21372224
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21
pubmed: 23359684
Clin Cancer Res. 1999 Mar;5(3):665-72
pubmed: 10100720
Gynecol Oncol. 2011 Jul;122(1):171-7
pubmed: 21453957
Cancer Res. 2001 May 1;61(9):3535-40
pubmed: 11325813
Cancer. 2011 Jul 15;117(14):3163-72
pubmed: 21246534
Int J Cancer. 1996 Mar 1;65(5):688-94
pubmed: 8598323
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Gynecol Oncol. 2010 Mar;116(3):419-23
pubmed: 19896181
Oncotarget. 2015 Sep 8;6(26):22496-512
pubmed: 26101915
BMC Clin Pathol. 2012 Nov 14;12:22
pubmed: 23151048
Clin Obstet Gynecol. 2011 Jun;54(2):292-304
pubmed: 21508698
Br J Cancer. 2008 Oct 21;99(8):1290-5
pubmed: 18813308
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243
pubmed: 27791010